Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. DFTX
10. IBM

Go back to Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)

Advaxis (ADXS) to Resume Trading at 4:34 pm ET

March 12, 2018 4:10 PM EDT

Advaxis (NASDAQ: ADXS) to Resume Trading at 4:34 pm ET

... More

Advaxis (ADXS) Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca's (AZN) IMFINZI

March 12, 2018 4:09 PM EDT

Advaxis (NASDAQ: ADXS) reported Q1 EPS of ($0.49), $0.06 better than the analyst estimate of ($0.55).

Clinical Hold

In the evening of March 9, 2018, the company received notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for its Phase 1/2 combination study of axalimogene filolisbac with IMFINZI (durvalumab) for the treatment of patients with advanced,... More